[3-(3-chlorophenyl)-[1,2,4]oxadiazol-5-ylmethyl]ethyl-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)amine | 870974-48-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: [3-(3-chlorophenyl)-[1,2,4]oxadiazol-5-ylmethyl]ethyl-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)amine
• 英文别名: N-[[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]methyl]-N-ethyl-4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-amine
• CAS: 870974-48-4
• 化学式: C₁₉H₁₈ClN₇O
• 分子量: 395.851
• InChiKey: HOPKVNKBZISLJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  85.8
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
  申请人：Edwards Louise

  公开号：US20050272779A1

  公开（公告）日：2005-12-08

  The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.

  本发明涉及公式I的新化合物，包含该化合物的药物配方，以及利用该化合物预防和/或治疗mGluR5受体介导的疾病的用途。
• ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
  申请人：Edwards Louise

  公开号：US20080045571A1

  公开（公告）日：2008-02-21

  The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.

  本发明涉及公式I的新化合物，包括含有该化合物的制药配方，以及该化合物在预防和/或治疗mGluR5受体介导的疾病中的使用。
• US7585881B2
  申请人：——

  公开号：US7585881B2

  公开（公告）日：2009-09-08
• [EN] ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS<br/>[FR] COMPOSES HETEROPOLYCYCLIQUES SUPPLEMENTAIRES ET LEUR UTILISATION COMME ANTAGONISTES DU RECEPTEUR METABOTROPIQUE DU GLUTAMATE
  申请人：ASTRAZENECA AB

  公开号：WO2006014185A1

  公开（公告）日：2006-02-09

  The present invention relates to new compounds of formula (I), to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.